IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4490
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$107K
Pending
Detailed business profile pending verification.
Headcount
—
HQ Base
TORONTO, Ontario
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$PBM PSYENCE BIOMEDICAL LTD. | 31 | 11 | 36 | 23 | 0.4x | -1.0x | 60.2% | 55.3% | - | - | - | -499.9% | 0.0% | 0.0x | $107K | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
PSYENCE BIOMEDICAL LTD. (PBM) receives a "Avoid" rating with a composite score of 30.6/100. It ranks #4490 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Executive Directory Unavailable for PBM
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
11
20
14
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for PBM
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for PBM.
View All RatingsInsufficient data for Financial Analysis
ROE proxy 60.2% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth -500%, 2yr history
Interest coverage -395.1x, Net debt/EBITDA -6.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags PSYENCE BIOMEDICAL LTD. with an Avoid rating, assigning a composite score of 30.6/100 and 1 out of 5 stars. Ranked #4490 of 7,333 stocks, PBM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
PSYENCE BIOMEDICAL LTD. registers a weak quality score of just 11/100, indicating significant profitability challenges. The company reports a return on equity of 60.2% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 36/100, PBM appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 0.43x, an EV/EBITDA of -0.99x, a P/B ratio of 0.38x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
PSYENCE BIOMEDICAL LTD.'s investment score of 20/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -499.9% vs. a sector average of 5.9% and a return on assets of 55.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PSYENCE BIOMEDICAL LTD. is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -499.9% year-over-year, while a beta of 1.23 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
PSYENCE BIOMEDICAL LTD. registers a low stability score of 14/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.23 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 51/100 for PBM suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.23), micro-cap liquidity risk. With a $107,125 market cap (micro-cap), PSYENCE BIOMEDICAL LTD. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
PSYENCE BIOMEDICAL LTD. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4490 of 7,333 overall (39th percentile). Key comparisons include ROE of 60.2% exceeding the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PBM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (11) would have the largest impact on the composite score.
EV/EBITDA 109% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 2528% BELOW SECTOR MEDIAN
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF MAR 31, 2025 (Q4 FY2024)
We rate PSYENCE BIOMEDICAL LTD. (PBM) as Avoid with a composite score of 30.6/100 at a current price of $2.18. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (36th percentile) and momentum (23th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (11th percentile) and stability (14th percentile) tempers our overall conviction. We assign a No Moat rating (37/100), High uncertainty, and Exemplary capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
PSYENCE BIOMEDICAL LTD. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.6/100 places it at rank #4490 in our full 7,333-stock universe. At $107,125 in market capitalization, PSYENCE BIOMEDICAL LTD. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -500% combined with momentum at the 23th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
Margin data is not available for PSYENCE BIOMEDICAL LTD., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $2.18, PSYENCE BIOMEDICAL LTD. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 0.4x (a 98% discount to the sector median of 22.3x), P/B of 0.4x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Returns on equity of 60.2% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Return on assets of 55.3% indicates efficient deployment of the full asset base, not just equity capital.
The Avoid rating (composite 30.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -500% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
We assign a High uncertainty rating to PSYENCE BIOMEDICAL LTD.. Key risk factors include below-average price stability (14th percentile), weak quality scores (11th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: below-average price stability (14th percentile); weak quality scores (11th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 14th percentile and quality factor at the 11th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (0% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate PSYENCE BIOMEDICAL LTD.'s capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 60.2%, disciplined leverage (0% D/E). Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — PSYENCE BIOMEDICAL LTD. meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 55.3% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, PSYENCE BIOMEDICAL LTD. receives a Avoid rating with a composite score of 30.6/100 (rank #4490 of 7,333). Our quantitative framework assigns a No Moat (37/100, trend: stable), High uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 21/100.
Our analysis does not support a constructive view on PSYENCE BIOMEDICAL LTD. at this time. The combination of limited competitive advantages, high uncertainty, and exemplary capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign PSYENCE BIOMEDICAL LTD. a meaningful economic moat, scoring 37/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, economic value creation, reached only 17.5/20.
The strongest moat sources are economic value creation (17.5/20) and margin superiority (10/20). ROE proxy 60.2% (sector -2.5%). GM N/A vs sector 43%, OM N/A vs sector 1%. These pillars form the core of PSYENCE BIOMEDICAL LTD.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect PSYENCE BIOMEDICAL LTD.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-500%) that pressure the earnings outlook, returns on equity of 60.2% driving shareholder value creation. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 11th percentile.
Return metrics include ROE of 60.2% and ROA of 55.3%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of 60.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of -500%. The sector median D/E is 0%, putting PSYENCE BIOMEDICAL LTD. in a relatively stronger balance sheet position. Overall balance sheet health is adequate for the current business environment.
Weak momentum (23th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (11th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election o
Psyence Biomedical has acquired an 11.13% stake in PsyLabs, a company focused on the cultivation and production of psychedelic active pharmaceutical ingredients. The acquisition is expected to benefit Psyence Biomedical's pipeline of psychedelic-based therapeutics.
Psyence Biomed has entered into an agreement to acquire an 11.13% stake in PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients. This acquisition will strengthen Psyence Biomed's relationship with PsyLabs and provide access to state-of-the-art cultivation and production capabilities.
Psyence Biomed has signed a conditional binding term sheet to acquire Clairvoyant, a clinical-stage developer of psilocybin-based therapeutics. Clairvoyant is currently executing a Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential treatment for Alcohol Use Disorder (AUD), with topline data expected in early 2025.
U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.